Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell Disease
NCT05392101
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
12
Enrollment
OTHER
Sponsor class
Conditions
Sickle Cell Disease
Interventions
DRUG:
Deferasirox 360 MG
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)